<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01003808</url>
  </required_header>
  <id_info>
    <org_study_id>IMF001J</org_study_id>
    <nct_id>NCT01003808</nct_id>
  </id_info>
  <brief_title>Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer</brief_title>
  <official_title>IMF-001 Phase 1 Study With Refractory Esophageal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImmunoFrontier, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ImmunoFrontier, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the biological recommended dose of IMF-001.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The prognosis of esophageal cancer is improved with the improvement of surgery, chemotherapy
      and radiation therapy. However, there are no standard therapies established for recurrent
      esophageal cancer. NY-ESO-1 antigen is expressed in 33% of patients. NY-ESO-1 protein is
      applicable without limitation by HLA types, and injected as a complex with cholesteryl
      pullulan (CHP), forming nano-particles (IMF-001), it can activate both CD4+ and CD8+ T cells.
      In this phase 1 study, the safety and the biological recommended dose will be determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the maximum tolerated dose, dose-limiting toxicities, type/frequency/degree of adverse events and NY-ESO-1 antigen-specific immune response of IMF-001 alone in patients with esophageal cancer.</measure>
    <time_frame>First 12 weeks (during the first 6 injections)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate clinical activity (tumor response and time to progression).</measure>
    <time_frame>Up to 2 years, or until progression of PS or no positive immune response from IMF-001.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>IMF-001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMF-001</intervention_name>
    <description>100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).</description>
    <arm_group_label>IMF-001</arm_group_label>
    <other_name>CHP-NY-ESO-1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Radically unresectable stage III/IV esophageal tumors that have failed the standard
             treatment (including chemotherapy and radiotherapy), recurrent metastasis after
             radical surgery and not responding to the standard treatments, or recurrent metastasis
             after radiotherapy before/after radical surgery.

          -  Primary esophageal tumors confirmed by pathological diagnosis

          -  Tumor cells expressing NY-ESO-1 antigen (by tissue-immunostaining method or
             quantitative RT-PCR method)

          -  Performance status (PS) of 0, 1 or 2 (ECOG Scale)

          -  Life expectancy &gt;/= 4 months

          -  No serious disorders with major organs (bone marrow, heart, lung, liver and kidney)
             and meets the following criteria:

               -  WBC count &gt;/= 2.0 x 10 9/L

               -  Hemoglobin &gt;/=8.0g/dL

               -  Platelet count &gt;/=75 x 10 9/L

               -  Serum total bilirubin: &lt;/=1.5 x ULN (3 x ULN if with liver mets)

               -  AST and ALT: &lt;/=2.5 x ULN (5x ULN if with liver mets)

               -  Serum creatinine: &lt;/=1.5x ULN

          -  Agree to use birth control including condoms from the time of obtaining the consent to
             6 months after the final administration of the study drug [except females after
             menopause (1 year or more after the last menstruation and females/males after an
             operation for sterilization)]

          -  Given written informed consent

        Exclusion Criteria:

          -  HIV antibody positive

          -  Double cancer

          -  History of autoimmune disease

          -  History of severe anaphylaxis

          -  Active metastatic disease in the central nervous system (CNS) Within 4 weeks after
             treatment with an anti-tumor agent, systemically administered adrenocorticosteroids,
             immune suppressants or immune enhancers

          -  Pregnant or lactating

          -  Any other inadequacy for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daiju Ichimaru, BSc</last_name>
    <role>Study Director</role>
    <affiliation>ImmunoFrontier, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>TSU</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitano Hospital</name>
      <address>
        <city>Kitano Hospital</city>
        <state>Osaka</state>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <reference>
    <citation>Aoki M, Ueda S, Nishikawa H, Kitano S, Hirayama M, Ikeda H, Toyoda H, Tanaka K, Kanai M, Takabayashi A, Imai H, Shiraishi T, Sato E, Wada H, Nakayama E, Takei Y, Katayama N, Shiku H, Kageyama S. Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine. 2009 Nov 16;27(49):6854-61. doi: 10.1016/j.vaccine.2009.09.018. Epub 2009 Sep 15.</citation>
    <PMID>19761832</PMID>
  </reference>
  <reference>
    <citation>Harada N, Hoshiai K, Takahashi Y, Sakaguchi Y, Kuno T, Hishida T, Shiku H. Preclinical safety pharmacology study of a novel protein-based cancer vaccine CHP-NY-ESO-1. Kobe J Med Sci. 2008 May 23;54(1):E23-34.</citation>
    <PMID>18772606</PMID>
  </reference>
  <reference>
    <citation>Tsuji K, Hamada T, Uenaka A, Wada H, Sato E, Isobe M, Asagoe K, Yamasaki O, Shiku H, Ritter G, Murphy R, Hoffman EW, Old LJ, Nakayama E, Iwatsuki K. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient. Cancer Immunol Immunother. 2008 Oct;57(10):1429-37. doi: 10.1007/s00262-008-0478-5. Epub 2008 Mar 1.</citation>
    <PMID>18311489</PMID>
  </reference>
  <reference>
    <citation>Uenaka A, Wada H, Isobe M, Saika T, Tsuji K, Sato E, Sato S, Noguchi Y, Kawabata R, Yasuda T, Doki Y, Kumon H, Iwatsuki K, Shiku H, Monden M, Jungbluth AA, Ritter G, Murphy R, Hoffman E, Old LJ, Nakayama E. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 2007 Apr 19;7:9.</citation>
    <PMID>17441676</PMID>
  </reference>
  <reference>
    <citation>Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, Kumon H, Tsuji K, Iwatsuki K, Shiku H, Ritter G, Murphy R, Hoffman E, Old LJ, Monden M, Nakayama E. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer. 2007 May 15;120(10):2178-84.</citation>
    <PMID>17278093</PMID>
  </reference>
  <reference>
    <citation>Hasegawa K, Noguchi Y, Koizumi F, Uenaka A, Tanaka M, Shimono M, Nakamura H, Shiku H, Gnjatic S, Murphy R, Hiramatsu Y, Old LJ, Nakayama E. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope. Clin Cancer Res. 2006 Mar 15;12(6):1921-7.</citation>
    <PMID>16551878</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2009</study_first_submitted>
  <study_first_submitted_qc>October 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2009</study_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

